Last mentioned: 4h ago
Across the most recent 5 stories covering Nasdaq — 40% positive, 60% neutral sentiment, averaging 5.6/10 impact.
This entity profile aggregates every story where the entity meets our minimum relevance threshold before it is linked here — a story naming this entity only in passing, as competitive context for an unrelated subject, does not qualify. That threshold exists because earlier testing surfaced entity pages cluttered with tangential mentions: a story about two unrelated companies merging could otherwise populate a third company's page simply because it was named once for comparison, with no real event of its own. The timeline below reflects genuine milestones and developments specific to this entity, cross-referenced against the same source-verification standard applied to every story on this site. Sentiment measures the directional read of each development for this entity specifically, not the overall tone of the reporting, and impact weights how consequential a development is rather than how widely it was syndicated across outlets.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Potential Extension
Aptorum may apply for a second 180-day period if compliance is not met but criteria are satisfied.
Initial Compliance Deadline
End of the first 180-day grace period to regain a $1.00 closing bid price.
Completion of Parallel Asset Acquisition
SNDL completed the transaction, obtaining indirect majority economic exposure to Parallel’s operations via Sunstream and TransactionCo.
Announcement of Parallel Transaction
SNDL publicly announced the planned acquisition of assets of Surterra Holdings (Parallel) through a strict foreclosure agreement.
Q4 2025 Earnings Call
Management discussed clinical progress of Lomecel-B and financial outlook.
Capital Raise
Entry into a material definitive agreement for the sale of unregistered equity securities.
NASDAQ Compliance Notice
Longeveron received notice of failure to satisfy NASDAQ listing rules.
Deficiency Notice Received
Nasdaq notifies Aptorum of non-compliance with the $1.00 minimum bid price rule.
The acquisition of Parallel gives SNDL indirect control over vertically integrated medical cannabis operations, potentially accelerating drug development and GMP-compliant manufacturing paths ahead of an expected Nasdaq consolidation.
Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.
Aptorum Group Limited (APM) has received a formal deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price required for continued listing. The company now enters a critical 180-day window to regain compliance, highlighting the ongoing financial pressures facing small-cap clinical-stage biotech firms.
Source: Seeking Alpha · Seeking Alpha
ImmunityBio (IBRX) shares rallied following the European Commission's marketing authorization of ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer. This milestone marks the first international expansion for the IL-15 superagonist, significantly broadening its global commercial reach.
Source: The Motley Fool · AOL.com
Beta Bionics and NeoGenomics reported robust Q4 2025 results, highlighting significant commercial momentum in autonomous insulin delivery and oncology diagnostics. Both companies emphasized operational efficiency and market expansion as key drivers for the upcoming fiscal year.
Source: insidermonkey.com · insidermonkey.com
This page surfaces every story mentioning Nasdaq across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
Entities only appear on this page once the classifier scores them at a minimum 35 percent relevance to the story, filtering out passing mentions. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Nasdaq was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |